The system, which the companies said will be available on select Samsung Galaxy devices, will enable users to control their insulin pump from their smartphone. The system is based around Insulet Corp.’s FDA-cleared Omnipod DASH insulin management system, a wearable insulin pump that delivers continuous insulin therapy to users.
Under the new system, Samsung Galaxy users would be able to manage their insulin therapy from an app. However, the solution has not yet been approved by the FDA.
“By integrating Samsung smartphones with drug delivery medical devices like Insulet’s Omnipod System, we’ve demonstrated that consumer-based digital health technologies can not only monitor and track one’s condition, but they can enable patient control of medical treatments,” said David Rhew, MD, CMO and vice president of enterprise healthcare at Samsung Electronics America.
“As chronic conditions like diabetes continue to increase in prevalence across all demographics, integrated partnerships between consumer technology and medical device companies, with support from regulators, will help establish a new paradigm of consumerism in healthcare in which medical care adapts to consumer lifestyle and preference,” he continued.
More articles on supply chain:
23andMe moves into pharmacogenetics as FDA greenlights new test
Homeland Security warns of vulnerabilities in Roche’s handheld medical devices
An opioid 10 times stronger than fentanyl, a reformulated asthma inhaler & more: 5 latest FDA approvals
